Novo Nordisk’s next-gen obesity drug CagriSema achieves lower weight loss than expected
Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, sending its shares down sharply.